60例非布司他治疗慢性肾功不全患者的高尿酸血症的临床分析  

Clinical Analysis of 60 Cases of Febuxostat in the Treatment of Hyperuricemia in Pa⁃tients with Chronic Renal Insufficiency

作　　者：王燕 WANG Yan(Department of Nephrology,Beijing Yanhua Hospital,Beijing,102500 China)

机构地区：[1]北京燕化医院肾内科,北京102500

出　　处：《世界复合医学》2022年第7期194-198,共5页World Journal of Complex Medicine

摘　　要：目的讨论60例非布司他治疗慢性肾功不全患者的高尿酸血症的临床观察。方法选取2019年5月—2021年8月北京燕化医院收治的慢性肾功能不全合并高尿酸血症患者60例,将其随机分为对照组(应用碳酸氢钠片治疗)与研究组(对照组基础上应用非布司他治疗),各30例,比较两组肾功能指标、肾小球滤过率、血清尿酸降低不同程度的时间、氧化应激指标、炎症因子及内皮细胞。结果治疗后,研究组尿素氮(17.16±1.13)mmol/L、尿微量白蛋白(226.64±55.83)mmol/L、血清肌酐(137.37±29.37)μmol/L及血清尿酸(308.85±25.43)μmol/L指标水平明显优于对照组,差异有统计学意义(P<0.05)。两组肾小球滤过率比较,差异有统计学意义(Z=-4.062,P<0.05)。研究组血清尿酸降低20%时间(5.53±1.35)周、血清尿酸降低40%时间(8.14±1.24)周均明显低于对照组,差异有统计学意义(t=6.823、9.367,P<0.05)。治疗后,研究组丙二醛(4.32±1.20)nmol/L、晚期氧化蛋白产物(82.33±10.52)nmol/L指标降低程度明显优于对照组,超氧化物歧化酶(104.52±8.34)ng/mL指标升高程度明显优于对照组,差异有统计学意义(t=4.634、13.635、2.221,P<0.05)。治疗后,研究肿瘤坏死因子-α(38.97±0.99)ng/L、白细胞介素1β(45.70±2.38)ng/L、白细胞介素-6(35.63±2.32)ng/L、内皮素-1(31.83±6.38)ng/L降低水平明显优于对照组,差异有统计学意义(P<0.05)。结论非布司他治疗慢性肾功不全合并高尿酸血症可显著改善患者肾功能及氧化应激水平,提高肾小球滤过率,降低尿酸水平及炎症反应。Objective To discuss the clinical observation of 60 cases of febuxostat in the treatment of hyperuricemia in patients with chronic re⁃nal insufficiency.Methods A total of 60 patients with chronic renal dysfunction and hyperuricemia were admitted to Beijing Yanhua Hospital from May 2019 to August 2021 were selected,and were randomly divided into a control group(treatment was performed with sodium bicar⁃bonate tablets)and a study group(treatment with febuxostat therapy on the basis of the control group),with 30 cases in each group,and the re⁃nal function indexes,glomerular filtration rate,the time of decreasing serum uric acid to different degrees,oxidative stress indexes,inflamma⁃tory factors and endothelial cells were compared between the two groups.Results After treatment,the indicators of blood urea nitrogen(17.16±1.13)mmol/L,urine microalbumin(226.64±55.83)mmol/L,serum creatinine(137.37±29.37)μmol/L and serum uric acid(308.85±25.43)μmol/L in the study group was significantly better than that of the control group,the difference was statistically significant(P<0.05).Comparison of the glomerular filtration rate between the two groups,the difference was statistically significant(Z=-4.062,P<0.05).The time of 20%reduction in serum uric acid(5.53±1.35)weeks and the time of 40%reduction of serum uric acid(8.14±1.24)weeks in the study group were significantly lower than those in the control group,the difference was statistically significant(t=6.823,9.367,P<0.05).After treat⁃ment,the indexes of malondialdehyde(4.32±1.20)nmol/L and advanced oxidized protein product(82.33±10.52)nmol/L in the study group were significantly lower than those in the control group,the level of superoxide dismutase(104.52±8.34)ng/mL was significantly higher than that in the control group,the difference was statistically significant(t=4.634,13.635,2.221,P<0.05).After treatment,tumor necrosis factor-α(38.97±0.99)ng/L,interleukin-1β(45.70±2.38)ng/L,interleukin-6(35.63±2.32)ng/L,endothelin-1(31.83±6.38)ng/L in the study g

关 键 词：慢性肾功不全 高尿酸血症 非布司他 

分 类 号：R589[医药卫生—内分泌]